Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27554373 | 0.85 | — | — | |
| SCHEMBL8267015 | 0.80 | LMNA (0.40) | GAAPOLBLMNAALDH1A1KDM4E | |
| SCHEMBL28236224 | 0.76 | GAA (0.38) | GAAPOLBFAAHPHGDHMGLL | |
| SCHEMBL1515457 | 0.75 | — | — | |
| SCHEMBL27666537 | 0.75 | — | — | |
| SCHEMBL1852780 | 0.72 | ALDH1A1 (0.48) | GAAPOLBALDH1A1HTTL3MBTL1 | |
| SCHEMBL28131216 | 0.72 | ALDH1A1 (0.48) | GAAPOLBALDH1A1HTTL3MBTL1 | |
| SCHEMBL6445312 | 0.72 | ALDH1A1 (0.39) | GAAFAAHPHGDHMGLLLMNA | |
| SCHEMBL4768884 | 0.72 | HSD17B10 (0.52) | GAAFAAHPHGDHMGLLLMNA | |
| SCHEMBL13671235 | 0.72 | LMNA (0.38) | GAAPOLBLMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104981470-B | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use | 拜耳制药股份公司 | 2017-04-19 | — | — | CN | disclosed |
| US-8088922-B2 | Dibenzorylenetetracarboximides as infrared absorbers | BASF AKTIENGESELLSCHAFT (DE) | 2012-01-03 | — | — | US | disclosed |
| EP-2029573-B1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF SE (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100048904-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048904-A1 | DIBENZORYLENETETRACARBOXIMIDES AS INFRARED ABSORBERS | TDO2, C9, CYP3A43 | GAA 4647/4885POLB 3004/4885FAAH 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.